Spyre Therapeutics SYRE
NASDAQ SYRE
$89.10 +1.85 (+2.12%)
As of: Sep 4, 2026 · 3:59 PM EDT

Spyre Therapeutics (SYRE) Total Debt (2023 - 2026)

Analysis

Spyre Therapeutics (SYRE) Total Debt (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.07 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.34 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 546.77 Mn
10 Spyre Therapeutics 7.53 Bn 7.53 Bn - 31.35 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 31.35 Mn
Mar 31, 2026 50.26 Mn
Dec 31, 2025 22.82 Mn
Sep 30, 2025 11.02 Mn
Jun 30, 2025 59.90 Mn
Mar 31, 2025 42.81 Mn
Dec 31, 2024 25.08 Mn
Sep 30, 2024 24.74 Mn
Jun 30, 2024 2.64 Mn
Mar 31, 2024 2.59 Mn
Dec 31, 2023 1.39 Mn
Sep 30, 2023 7.51 Mn
Jun 30, 2023 185.19 Mn